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Abstract
Mesenchymal stem cells (MSC) have a therapeutic potential in patients with fractures to reduce
the time of healing and treat non-unions. The use of MSC to treat fractures is attractive as it would
be implementing a reparative process that should be in place but occurs to be defective or
protracted and MSC effects would be needed only for the repairing time that is relatively brief.
However, an integrated approach to define the multiple regenerative contributions of MSC to the
fracture repair process is necessary before clinical trials are initiated. In this study, using a
stabilized tibia fracture mouse model, we determined the dynamic migration of transplanted MSC
to the fracture site, their contributions to the repair process initiation and their role in modulating
the injury-related inflammatory responses. Using MSC expressing luciferase, we determined by
bioluminescence imaging that the MSC migration at the fracture site is time- and dose-dependent
and, it is exclusively CXCR4-dependent. MSC improved the fracture healing affecting the callus
biomechanical properties and such improvement correlated with an increase in cartilage and bone
content, and changes in callus morphology as determined by micro-computed-tomography and
histological studies. Transplanting CMV-Cre-R26R-LacZ-MSC, we found that MSC engrafted
within the callus endosteal niche. Using MSC from BMP-2-Lac-Z mice genetically modified using
a bacterial artificial chromosome system to be β-gal reporters for BMP-2 expression, we found
that MSC contributed to the callus initiation by expressing BMP-2. The knowledge of the multiple
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MSC regenerative abilities in fracture healing will allow to design novel MSC-based therapies to
treat fractures.
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INTRODUCTION
High energy tibia fractures are threatening injuries with slow healing times averaging 43–49
weeks 1. Furthermore, the fracture healing process is impaired in 10–20% of the fractures,
resulting in non-unions and causing severe disabilities 2–4. Non-unions are mostly treated
with bone autografts that are associated with morbidities related to the harvesting procedure,
have a limited supply and unpredictable repairing potential 5. There is a compelling need to
develop novel therapies to improve the fracture healing course and to treat non-unions.
Mesenchymal stem cells (MSC) initiate the fracture repair process leading to the formation
of a cartilaginous template (callus) that is then replaced by new bone that repairs the gap 6.
Limitation in MSC number and/or functions are hypothesized to play a critical in the
pathogenesis of non-unions. MSC are present in several adult tissues including bone marrow
(BM) and are capable of differentiating in vitro into mesenchyme cell types including
chondrocytes and osteocytes while such differentiation has not been unequivocally shown in
vivo 7. Furthermore, both BM-MSC and BM mononuclear cells have been reported to exert
beneficial effects in the healing of a limited number of patients with non-unions 8–13.
Although promising, these clinical studies are anecdotal. Before controlled clinical trials can
begin, critical animal studies are necessary to determine how MSC are recruited and survive
at the fracture site, their repair effectiveness and the mechanisms through which they exert
their actions.
Although MSC seem to migrate into damaged tissues, their dynamic trafficking and tissue
homing when systemically infused is a poorly understood process 14–16. Post-mortem
microscopy is the standard method to detect transplanted MSC within the tissues; however,
it does not allow to study either the cell trafficking or to perform longitudinal observations
and it is not quantitative. Small-animal in vivo imaging bioluminescence (BLI) permits to
determine a semi-quantitative temporal and spatial analysis and bio-distribution of the light
signal of luciferase-tagged cells within a living animal. Among chemokines and their
receptors, CXCR-4 has been found to be critical in hematopoietic stem cell homing and
cancer cell metastasis 17. The CXCR4 expression and contribution to MSC migration in
vitro and its need in MSC homing in vivo has been scarcely evaluated 18, 19.
Several reports have shown that MSC delivered to an injured tissue can improve the
recovery; however, a limited number of MSC have been demonstrated to differentiate into
the repaired tissue 20–22. This discrepancy might be explained by the fact that: 1) there are
technical difficulties in identifying MSC within the repaired tissue; 2) studies have focused
on the identification of MSC differentiation into cells involved in advanced stages of
healing; 3) MSC mechanisms of action, other than differentiation, may have induced the
regeneration. Anti-inflammatory paracrine effects of MSC have been reported in animal
models of acute and chronic inflammatory diseases 23–26. Most recently, MSC transplant in
55 patients with severe graft-versus-host disease has led to a complete response or
improvement in 39 patients 27. It is plausible that due to their intrinsic multipotentiality,
MSC have several and distinct reparative actions. Uncontrolled inflammation plays a critical
role in the pathogenesis of non-unions and a selective modulation of the inflammatory
response may become the target of new therapies to enhance the bone repair and to prevent
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the occurrence of a non-union. The role of MSC in the initiation of the callus formation has
been scarcely investigated and most of the studies have focused on more advanced repair
stages either during the cartilageneous callus maturation or the mineralization process 28, 29.
Our studies were designed to determine: 1) the in vivo trafficking and homing within the
fractured tibia of systemically transplanted MSC; 2) the need of CXCR4 for MSC homing;
3) the effects of MSC transplant in the callus biomechanical properties; 4) the MSC
engraftment into the repairing tissue and contribution to the callus initiation; 5) the systemic
and local anti-inflammatory effects of MSC in fracture repair.
MATERIALS AND METHODS
Reagents
7-Amino-actinomycin D (7-DAA) was from Molecular-Probes; D-luciferin from Biosynth-
International.
Antibodies
Biotin-conjugated anti-mouse CD34, CD45, CD11b and CXCR4 antibodies from BD-
Biosciences. Phycoerythrin-conjugated anti-mouse CXCR4, CD29, CD44, CD73, CD105,
CD45 and control isotype antibodies from eBioscience.
Stabilized fracture model
All animal procedures were approved by the animal care committee of the University of
North Carolina-Chapel Hill and Vanderbilt University. Stabilized tibia fractures were
produced in 8–12 weeks old FVB female syngenic mice (FVB-NJ, Jackson-Laboratories) by
intramedullar fixation using a 0.25mm stainless steel pin (Fine-Science-Tools) inserted
through the patellar tendon inside the medullar canal of the tibia followed by closed fracture
using a three-point bending device with a standardized force 30. For pain control,
bupremorphine (0.5 mg/kg) was administered subcutaneously.
Isolation and expansion of MSC
Primary cultures of BM-MSC were obtained by flushing the BM from femurs and tibias of
4–6 weeks old FVB-NJ mice as previously reported 31. Briefly, BM nucleated plastic-
adhering cells were expanded for 7–10 days without passaging 31. Immediately before
transplant, contaminating hematopoietic cells were eliminated by immunodepletion of the
CD45, CD11b and CD34 positive cells using a MACS system (Miltenyi-Biotech). As shown
in Supplemental Fig. 1, using this protocol we obtain a MSC population in which >90% of
cells express the specific MSC markers CD73, CD29, CD44, and 67.5% the CD105 marker.
Furthermore, MSC after immunodepletion were negative for CD45 (0.9±0.5%, n=3) and
CD11b (1.1±1.3%, n=3). For BLI imaging, MSC were isolated from FVB/N animals
constitutively expressing Firefly luciferase under the β-actin promoter (FVB/N-Tg(β-Actin-
luc)-Xen) (Caliper-Life-Sciences). After fracture, mice were transplanted with 106 MSC by
tail vein injection, unless specified. MSC were also isolated from the BM of the CMV-R26R
or BMP-2-Lac-Z mice and transplanted into wild-type female littermates. The BMP-2-Lac-Z
and CMV-R26R mice were generated as described in the Online Supplemental Materials or
previously reported 32.
BLI analyses
BLI imaging was performed using an IVIS 200 imaging system (Caliper-Life-Sciences). All
images were collected 15 minute after D-luciferin (150 mg/kg) intraperitoneal injection.
Additional information on the BLI analyses are available in the Online Supplemental
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Materials. BLI signaling at the fracture tibia site region of interest (ROI), measured as
integrated photons/sec/cm2/sr, was normalized by subtracting the background signal found
in an equal ROI in the contralateral intact tibia. Imaging data were analyzed using the
LivingImages2.20.1 (Xenogen-Corp.).
Luciferase expressing adenoviruses and MSC infection
An adenoviral vector that encodes the Firefly luciferase under the control of a
cytomegalovirus promoter was used to generate highly purified (CsCl gradient) viruses as
previously described 33. All the experiments were performed using a multiplicity of
infection of 1,000 in MSC cultured for 7 days. Additional information are provided in the
Online Supplemental Materials.
Biomechanical testing (BMT)
Fractured tibias were dissected 14 days post-fracture, wrapped PBS-embedded gauze and
stored at −80°C until analysis. The bone ends were embedded with polymethylmetacrylate
and loaded into the electroforce-based system ELF 3100 (Bose). The displacement rate was
at 0.25 mm/min and a force-displacement curve recorded to calculate the ultimate distraction
(maximum distraction at failure), ultimate force (maximum force at failure), toughness (area
under the curve) and stiffness (maximum slope) using the WinTestControl Software (Bose).
Histology and in situ hybridization
Tibias were dissected 7 and 14 days post-fracture, histologically prepared and the entire
callus sectioned (6μm). The callus center was identified as the largest diameter by H&E
staining and analyses performed within 20 sections from the center. In situ hybridization
analysis was performed as previously reported 34. Plasmid with insertion of mouse Collagen
(II)-alpha1-chain (Col2a1) was provided by D. Kingsley (Stanford University), mouse
Collagen (I)-alpha-1-chain (Col1a1) and mouse Osteocalcin by G. Karsenty (Columbia
University),. Probe for mouse Collagen (X)alpha1chain (Col10a1) was generated as
previously described 35. Images were taken using an Olympus BX51 microscope with a
DP71 camera, imported into Adobe Photoshop and formatted without using any imaging
enhancement.
Micro computed tomography μCT) analysis of fracture calluses
Tibia fractures were dissected 14 days post-fracture, and following removal of the pin and
μCT scanned (Scanco Medical 3CT40). μCT imaging were obtained at 55 kVp, 145 μA,
300 ms integration time using 63m voxel resolution along 5.2 mm length centered at the
fracture line with a total scanning time of approximately 1 hour36. To determine material
type from μCT scans, a parametric thresholding study was performed by serial μCT
scanning and histological analysis as reported in the Online Supplemental Materials.
Circulating and callus cytokine measurements
Sera were obtained from mice that received MSC transplant and controls at day 1, 3 and 7
post-fracture. Tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), interleukin-10
(IL-10), interleukin-13 (IL-13), interleukin-6 (IL-6) levels were determined using
LINCOplex immunoassay (LINCO-Research). Total RNA obtained using Trizol and
PureLinK columns (Invitrogen) from dissected calluses 3 and 7 days after fracture was
reversed transcribed using SuperScript III reverse transcriptase (Invitrogen) and
Oligod(T)16 (Applied Biosystems). TNF-α mRNA expression was measured by qRT-PCR
(MyIQ-Single-Color-RT-PCR-System, Biorad) using Syber Green as previously
described 37. PCR primers for TNF-α amplification were: 5′-
CCACCACGCTCTTCTGTCTAC-3′ and 5′-GGCTACAGGCTTGTCACTCG-3′. Samples
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were run in triplicates, data were normalized to β-actin expression and analyzed using the
2−ΔΔCT method and expressed as fold of increases compared with the average of an
untransplanted control, which was given the value of 1.
X-Gal staining
X-Gal staining was performed as previously described with some modifications 32. Briefly,
the fractured tibia was dissected, briefly fixed with 0.4% PFA and stained at room
temperature with X-Gal staining solution. To achieve specific localization of cells which
express prokaryotic (Escherichia coli) β-galactosidase, pH of the reacting solution was
adjusted to selectively favor its activity over that of the mammalian enzyme 38, 39. After
staining, samples were fixed with 4% PFA for 24h paraffin embedded and sections were
counter-stained using nuclear fast red as previously described 32, 35. CMV-R26R-LacZ-
MSC (1×105) were placed in 10μl medium in a 24-well plate and after 1 hour, 500μl of
medium was added; cells were cultured for 24 hours and X-Gal stained as previously
reported 35.
Statistics
Data are expressed as mean ± SD. Statistical analyses were performed using unpaired
Student’s t-test, ANOVA followed by post-hoc multiple comparison testing. the relationship
between number of transplanted MSC and BLI signal was analyzed using a dose-response
sigmoid curve. The Graph-pad Prism Software was used. Statistical significance was set at
p<0.05.
Online supplemental materials
Online supplemental material is available.
RESULTS
Systemically transplanted MSC: in vivo dynamic and time-dependent recruitment at the
fracture site
To assess the in vivo MSC dynamic trafficking and homing in response to a pathological
tibia fracture cue, 1×106 MSC-β-Act-Luc, constitutively expressing luciferase, were
transplanted into a mouse with stabilized tibia fracture and sequential BLI imaging was
performed from day 1 to day 14 post-fracture/transplant. As depicted in Fig. 1A (left panel),
one day after the fracture/transplant MSC-β-Act-Luc were visualized at the lung site. On
day 3 after the fracture, we observed that MSC began to localize at the fractured leg site
(right tibia) where they persisted up to 14 days after the fracture/transplant (Fig. 1A, left
panel). Semi-quantitative analysis of the BLI signal of luciferase-tagged MSC over the
fractured leg, was time-dependent, increasing progressively from day 1 to day 7, without
any further increase at day 14.
The presence of CXCR4 is essential for MSC homing at the fracture site
The finding that MSC have the ability to migrate to an injured tibia implies that they own
specific homing signal(s). While CXCR4 has been involved in the hematopoietic stem cell
engraftment and cancer cell metastasis, its role in MSC homing still needs to be
defined 18, 19, 40–42. In our study, using primary cultures of unpassaged MSC
immunodepleted of hematopoietic cells, we first found that ~30% of MSC express CXCR4
(34.2±4.7%, n=4 MSC cultures obtained from the BM of at least 4 mice for each culture).
Second, we separated, using CXCR4 immunoselection, the MSC population as MSC-
CXCR4(+) and MSC-CXCR4(−) populations that were injected into a mouse with a tibia
fracture. One day post-fracture both MSC-CXCR4(+) and MSC-CXCR4(−) had a
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localization pattern similar to the unselected MSC (Fig. 1A). However, at day 3, MSC-
CXCR(−) were not capable of homing to the fracture site, while the MSC-CXCR(+) showed
an intense signal (Fig. 1A, middle and right panels). A similar scenario was observed at day
7 and day 14 following the fracture/transplant (Fig. 1, middle and right panels). As shown in
Fig. 1B, semi-quantitative analysis of the BLI signal confirmed that the MSC-CXCR4(−)
migration to the fracture site at any studied time-point was negligible; whereas, MSC-
CXCR4(+) showed a time-dependent increase of MSC-luciferase signal at the fractured
tibia. Our data demonstrate that systemically transplanted MSC are capable of homing at the
fracture site and the migration is dependent on the presence of CXCR4.
Dose-dependent MSC homing at the fracture site
To assess the dose-dependent MSC homing at the fracture site, we systemically infused
MSC transduced with an adenoviral vector expressing luciferase (MSC-Adn-Luc) into mice
with a tibia fracture. We reasoned that since adenoviruses do not integrate in the host
genome, and expression is lost in dividing cells, the luciferase signal would exclusively
assess the MSC migration to the fracture site. As shown in Supplemental Fig. 3A, in mice
with fractured tibia transplanted with increasing doses of MSC-Adn-Luc (from 5×103 to
1000×103 MSC) and BLI imaged 3 days later, we found that MSC homing was dose-
dependent. Interestingly, we found the ED50 to be a dose of 300×103, with a plateau at
700×103 without any significant increase at a dose of 1000×103 (Supplemental Fig. 3C).
This finding indicates that MSC migration to the injured site reaches a saturation point and a
limiting mechanism that needs further investigations can be hypothesized.
MSC improve the biomechanical properties of the fracture callus
A critical feature of bone healing is that the regenerated tissue provides sufficient strength to
the injured limb in order to regain function. To investigate whether MSC improved the
callus material properties we performed distraction-to-failure BMT. Dissected calluses from
MSC recipient mice (MSC) as well as control calluses from mice that did not receive MSC
(no cells), were subjected to a gradual distraction force until they broke. As shown in Table
1, calluses of mice that received MSC had increased toughness and ultimate displacement
compared to controls. The peak force was not different in the two groups while, there was a
trend over a decrease of callus stiffness in the mice that received MSC. Taken together,
these data indicate that MSC improved the callus material properties making the tissue less
brittle by decreasing the structural rigidity.
MSC effects on callus size and morphology
To determine material type (bone and soft tissue) from μCT scans, a parametric threshold
study of an entire callus was performed by serial μCT scanning and histological analyses (in
situ hybridizations for Collagen 1, Collagen 10, and Trichrome-Blue and Safranin-O/Fast-
Green staining) (see Supplemental Materials). Mice that received MSC transplant displayed
a significant increase of the total volume, as well as total bone, soft tissue, new bone, and
callus volumes and callus mineralization content compared to controls (Fig. 2A). The three-
dimensional reconstructions of the entire calluses as well as the sagittal sections showed
remarkable differences in the size and morphology of the new mineralized callus in mice
that received MSC versus controls. As shown in Fig. 2B, the most notable differences were
that: 1) a large callus surrounded the fractured bone edges as well as the intact cortical bone
in the calluses from mice transplanted with MSC, but remained limited to the ends of the
bone segments in the controls [compare panels B1 with B5 and B3 with B7]; 2) a continuous
net of the creeping callus bridging the fracture gap in MSC recipient mice versus the limited
connectivity observed in the controls [compare panels B2 with B6 and B4 with B8]. These
findings indicate that MSC transplant by providing a more organized bridge between the
bone ends improves the repairing process and therefore its material properties.
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MSC effects on callus histology
We next analyzed the callus histology as well as bone and cartilaginous marker expressions
at day 7 and 14 after the fracture and MSC transplant. H&E staining analyses, showed that
at 7-days, the calluses from mice transplanted with MSC were bigger than controls and
demonstrated larger areas of cartilage-like tissue (Fig. 3A). In situ hybridization for
Collagen 2 and Collagen 10 expression as well as Safranin-O staining revealed a more
abundant presence of either chondrocytes or hypertrophic chondrocytes in the calluses from
mice transplanted with MSC, indicating that the fracture repair in those mice more
predominately proceeded through an endochondral ossification process than controls (Fig.
3A). When evaluated at 14 days after the fracture, Collagen 10 expression was also
consistently higher in mice that received MSC than controls and at this time, it was
associated with an increase of Collagen 1 expression indicating that the endochondral callus
progressed to bone formation (Fig. 3B).
MSC distribution within the callus
To analyze the cellular distribution of transplanted MSC within the callus, fractured mice
were transplanted with MSC from CMV-R26R mice and 7 days after fracture-transplant
dissected calluses were Lac-Z stained. As shown in Supplemental Fig. 4, CMV-R26R-LacZ-
MSC express stainable β-Gal activity, indicating this as a suitable reporter system for MSC.
As negative control for the Lac-Z staining protocol, 7-day post fracture calluses from wild-
type mice were Lac-Z stained. As shown in the Supplemental Fig. 5, no staining was
detectable indicating that the protocol used did not result in any background.
As shown in Fig. 4A, we found that transplanted CMV-R26R-LacZ-MSC localized within
specific areas of the callus, in particular within the fracture ridge, the endosteum close to the
fracture rim and the BM. Counterstaining the calluses with Safranin-O/Fast-Green (Fig. 5B),
we identified that MSC localized within the endosteal callus in the areas of most active bone
formation. Higher magnification of these areas showed that the Lac-z positive MSC (stained
in Blue) were embedded in the bone matrix (stained in Green) as osteoblasts within the
newly forming bone (Fig. 5C) or as newly formed osteocytes with abundant cytoplasm (Fig.
5D). As shown in Supplemental Fig. 6, in situ hybridization analysis confirmed that within
the margins of the woven bone, some of the Lac-z positive MSC expressed also osteocalcin
confirming their ability to differentiate into osteoblasts. Our findings indicate that
transplanted MSC localize within different and specific niches of the callus and the number
of MSC within the newly forming bone seems to be limited compared to the significant
effects of MSC on the callus biomechanical properties. This observation led us to
hypothesize that the contributions of MSC to the fracture healing is likely through multiple
mechanisms that include but cannot limited to the callus mineralization.
MSC contribute to the callus initiation by expressing BMP-2
To determine the contribution of MSC to the initial phase of the callus formation, we
analyzed whether transplanted MSC were capable of expressing BMP-2 within the callus.
BMP-2 is highly expressed during fracture healing and is essential for the callus
initiation 43. In fact, in mice null for BMP-2 expression in limb mesenchyme progenitors,
the earliest steps of fracture healing are blocked and mice lack fracture healing 43. For this
purpose, we obtained MSC from BMP-2-Lac-Z mice genetically modified using a BAC
system to be β-gal reporters for BMP-2 expression 32. BMP-2-Lac-Z–MSC were
transplanted into fractured mice, calluses were dissected 7 days after the fracture and Lac-Z
stained. We found that BMP-2-Lac-Z-MSC localized within the fracture rim and more
peculiarly along the endosteum adjacent to the fracture edges (Fig. 5A–B). This pattern was
similar to the pattern observed in the fractured mice transplanted with CMV-R26R-LacZ-
MSC, although the mice transplanted with BMP-2-Lac-Z–MSC lacked the Lac-Z staining
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within the BM cells. Our data indicate that transplanted MSC localize at the fracture site and
are capable of expressing BMP-2, an essential gene for initiating the fracture repair process.
To determine the endogenous BMP-2 expression at the same fracture healing stage, calluses
were obtained 7 days after fracture from BMP-2-Lac-Z fractured mice and Lac-Z stained.
As shown in Fig 5C–D, we found that BMP-2 is highly expressed at the fracture rim and
interestingly no expression was detectable at the endosteal site. This observation may
indicate that the endosteum is a peculiar niche where the transplanted MSC engraft and
express BMP-2.
MSC transplant modulates the systemic and local inflammatory responses
To determine whether the beneficial contributions of MSC to the fracture healing was
associated with an anti-inflammatory action, we sequentially determined the circulating
levels of a set of cytokines in the serum of mice either transplanted with MSC or controls.
As shown in Fig. 6, over the first week after the fracture, MSC transplant selectively down-
regulated the serum levels of TNF-α and IL-1β abolishing the injury-induced inflammatory
response found in the control fractured mice. The MSC anti-inflammatory action was
targeted to specific cytokines, in fact, MSC had no effect on IL-13 and IL-10 at any time and
had only a significant effect reducing IL-6 levels at day 3 post-fracture (Fig. 6C–E). MSC
had similar effects on the local mRNA expression of TNF-α that was decreased in the
calluses from MSC transplanted mice compared to controls at day 3 (MSC: 1.278±1.741
fold of change; control: 3.78±3.006; P<0.05; n=6) and day 7 (MSC: 0.670±0.315 fold of
change; control: 2.729±2.334; P<0.05; n=6) post-fracture.
DISCUSSION
In our studies, we have characterized, in living animals, the dynamic migration of MSC in
response to a bone fracture and determined that this specific migration at the site of injury is
driven by CXCR4. We have also demonstrated that MSC transplant induces a biomechanical
improvement of the healing process that is associated with an increase in the callus volumes
and cartilageneous and bone contents. We have found that MSC engraft into specific niches
of the callus expressing the fracture repair initiator BMP-2 and that the delivery of MSC has
a specific systemic and local anti-inflammatory effect. In summary, our report provides a
comprehensive assessment of the contributions of transplanted MSC to the fracture healing
process.
There is a significant body of evidence that links MSC to tissue regeneration, including bone
and cartilage 20. However, in vivo studies have been primarily performed using post-mortem
analyses; as a result longitudinal evaluations of MSC dynamic in living animals are
scarce 15. Furthermore, studies have been limited in the attempt to demonstrate one of the
regenerative effects of MSC, mostly the differentiation into bone, lacking an ample
evaluation of the multiple actions of MSC. The regeneration of damaged tissue implies that
different responses converge at the damaged area. The regenerative cells need to be
recruited at the injury site, control the injury-induced responses and eventually contribute to
the repair. In our studies, we have demonstrated that MSC exert their regenerative properties
by contributing to each of the stages of fracture healing. Transplanting MSC tagged with
luciferase in combination with BLI analysis, we have demonstrated that MSC migrate to a
fracture site and migration is time- and dose-dependent. Recruitment of circulating
progenitor cells to the site of injury occurs as a normal biological process during the fracture
process 44. We hypothesize that MSC injected systemically migrate to the fracture site using
a similar injury-related recruitment mechanism. Gao et al, using 111I-indium-MSC
investigated the MSC dynamic only for 48 hours after cell infusion into normal non-injured
rats 15. Authors found that after injection, cells distributed into the lungs and the liver and a
vasodilator increased the liver localization 15. We found similar results in our short-term
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BLI studies, but our long-term analyses in fractured mice allowed us to determine that three
days after the fracture/transplant, MSC were specifically recruited at the fracture site where
they remained up to 14 days. Thus, the use of MSC transplant seems to be a valid strategy to
allow a non-invasive increase of viable progenitors at a fracture site.
We have found that fracture MSC migration is dependent on the presence of CXCR4. There
are discordant data on whether MSC express CXCR4 and its role in MSC
migration 18, 19, 40–42. Differences in culture passages may be the reason for such
discordances; in fact, cell passaging causes a down-regulation of CXCR4 expression and
loss of MSC homing 18, 45, 46. We have used primary cultures of unpassaged MSC
immunodepleted of hematopoietic cells and found a consistent CXCR4 expression in ~30%
of the MSC population. Cheng et al., have recently reported that MSC recruitment was
enhanced in a rat model of myocardial infarction by retrovirally overexpressing CXCR-4 in
MSC that lacked CXCR447. In our study, we have found that, without any CXCR-4
manipulation, native primary cultured MSC are capable of homing at a fracture site in a
CXCR4 dependent manner.
In our study, we found that MSC transplant improves the fracture healing by increasing the
material toughness of the callus and causing it to be less brittle. The observed biomechanical
material data were consistent with the μCT imaging that showed in MSC recipient mice
some remarkable differences in the callus geometry that was larger with more organized
bridging structures characterized by soft tissue and new bone. Histological analyses
confirmed that the fracture healing in MSC recipient mice progressed through more cartilage
and newly mineralized bone than controls. Tibia fractures necessitate long period for
healing. Optimization of clinical management can reduce the healing time, however it has
been pointed out that even if osteogenic cells at the fracture site are working at full capacity,
they will not heal the defect if too few cells are present, nor will any drug, directed at
enhancing bone formation be effective since maximal osteogenesis per cell is already
occurring 48. Our studies provide evidence that even in a normal fracture healing tibia
model, MSC transplant enhances the repair process supporting the use of MSC to provide a
critical number of regenerative cells to achieve the desired bone-repairing results in patients
with high-energy fractures. Although some non-union animal models are available, these
models are based either on mice with genetic defects that lead to repair impairments, or by
creating large bone gaps or stripping the periosteum in order to decrease the number of
regenerative progenitors. None of these models reflects the mechanisms for non-unions
found in patients. Furthermore, the healing times in those models are largely inconsistent
making problematic the interpretation of results when multiple experimental groups are
studied. On the other hand, the stabilized fracture tibia model we have used has a consistent
healing time and having found that in this model, MSC have several positive effects opens
optimistic prospective for using MSC in non-unions.
In our studies using Lac-Z tagged MSC, we found that transplanted MSC localize along the
margins of woven bone where they assume the morphology of active osteoblasts, express
osteocalcin and associate with the endosteal surface. Interestingly, MSC did not localize
within the periosteal callus although the overall size of the callus of MSC transplanted mice
was larger and showed larger areas of newly forming bone. This observation led us to
pursue studies aimed at determining whether the MSC regenerative effects were not
exclusively related to their differentiative abilities into bone but also to their contributions
on the initiation of the healing process. Our study is the first to report that systemically
injected MSC localize at the fracture site where they are capable of expressing BMP-2, an
essential initiator of the fracture repair process 43. One interesting finding from our study is
that MSC expressing BMP-2 localize very distinctly at the endosteum site. The endosteum
maintains the bone homeostasis, participates in the fracture healing process and a lack of the
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endosteal callus formation is critical in the pathogenesis of non-unions 49–51. Several cells
form the endosteal niche including osteoblasts, CXCL12-abundant reticular (CAR) cells,
MSC and hematopoietic stem cells. There is a large body of evidence that support the notion
that the endosteal osteoblasts provide a variety of factors that regulate the hematopoietic
stem cell number and function [reviewed in 52, 53]. It has been hypothesized that in the
endosteal niche CAR cells together osteoblasts, and potentially other cell types, generate a
hypoxic environment that maintains the hematopoietic stem cells in a quiescent state 53. The
inhibitory effect of MSC on cell proliferation in vitro raises the possibility of a MSC role in
maintaining the hematopoietic stem cells in this quiescent state 54. On the other hand,
hemapotopoietic stem cells regulate MSC induction into osteoblasts in vitro as well as ex-
vivo 55. Our knowledge of the MSC niches within native tissues is very poor and even less is
known about the MSC niches after transplant. Our study provides evidence for the homing
of circulating transplanted MSC in response to a fracture injury cue into the endosteal niche,
where they express BMP-2. It is plausible that MSC expressing CXCR4 are recruited to the
endosteal niche by CAR cells. We hypothesize that MSC within the endosteal niche can
either differentiate into osteoblasts, or through a paracrine action, control the injury-related
inflammatory response. It will be of great interest to evaluate in future longitudinal studies
the contributions of MSC through all the reparative process.
Several studies have shown that MSC have the ability to suppress the inflammatory response
in vitro as well as in vivo (reviewed in 20, 22). These anti-inflammatory effects were induced
through paracrine mechanisms that shifted the tissue milieu from a pro-inflammatory to an
anti-inflammatory state 23–26. During the tissue repairing process a precise temporal and
spatial resolution of the inflammatory response is critical to limit the tissue injury, to prevent
the development of fibrosis, and ultimately to promote the regeneration. Uncontrolled
inflammation plays a critical role in the pathogenesis of non-unions. Traditional anti-
inflammatory drugs that block the cytokine response in toto are unable to direct and
selectively control the process and may actually have negative effects on the healing
process. In our study, we have found that the beneficial effects of MSC transplant on
fracture regeneration are associated with a selective effect on systemic and local cytokine
production. MSC as selective modulators of the inflammatory response may become the
target of new therapies to enhance the healing process in patients with non-unions.
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In summary, we have determined that transplanted MSC improve the fracture repair
process and we have elucidated several of the mechanisms involved in these beneficial
effects. We have characterized the dynamic of MSC migration and the essential role of
CXCR4, we have found the niches for MSC recruitment at the injury site and we have
determined that MSC contribute to the fracture healing by expressing BMP-2 and
modulating the injury-related inflammatory response. Our findings provide some critical
information to implement the development of MSC-based therapies in patients with
poorly healing fractures.
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Figure 1. MSC migrate to the fracture site in a time- and CXCR4-dependent manner
(A): BLI was performed at day 1, 3, 7 and 14 after fracture/transplant in mice with tibia
fracture transplanted either with 106 MSC-β-Act-Luc (MSC) (left panel), MSC-β-Act-Luc-
CXCR4+ (CXCR-4+) (middle panel) or MSC-β-Act-Luc-CXCR4-(CXCR-4−) (right panel).
Graded color bar indicates BLI signal intensity expressed as photons/sec/cm2/sr. (B): BLI
signal semi-quantitative analysis. Signal at the fracture tibia site ROI measured as photons/
sec/cm2/sr, was normalized by subtracting the background signal found in an equal ROI in
the contralateral unfractured tibia. a p<0.05 versus CXCR4-group; b p<0.01 versus CXCR4-
group; c p<0.05 versus MSC by Tukey post-test. Abbreviations: MSC, mesenchymal stem
cells.
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Figure 2. MSC transplant increases callus size and changes callus morphology
(A): μCT analyses were performed 14 days after fracture in calluses dissected from mice
that received MSC transplant and controls (no cells). Callus volume and new bone volume
were calculated after subtracting the cortical bone volume respectively from the total
volume and the total bone tissue volume. #, p<0.05 versus No cells; ##, p<0.01 versus no
cells by Student’s t-test. No cells, n=3; MSC, n=6.
(B): three-dimensional reconstruction of whole calluses (B1, B2, B5, B6) and sagittal
sections (B3, B4, B7, B8) were obtained 14 days after tibial fracture in calluses from mice
that were transplanted with MSC or control untransplanted (no cells). Material type analysis
of new bone, and soft tissue was determined by a histological-based thresholding of the μCT
imaging scans. Abbreviations: MSC, mesenchymal stem cells.
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Figure 3. MSC transplant increases the cartilageneous and bone content of the callus
(A): transversal sections of 7 days post-fracture calluses were subjected to H&E and
Safranin O staining and in situ hybridization for Collagen-2 and Collagen-10. (B): 14 days
post-fracture transversal sections were subjected to H&E staining and in situ hybridization
for Collagen-1 and Collagen-10. The entire callus was sectioned (6 μm thick sections), the
center of the callus was identified by the largest diameter of callus size by H&E staining and
further analyses were performed within 20 sections from the center. Analyses were done in
at least 5 sections for each probe or staining. Sections were obtained from at least 3 mice for
each group. Abbreviations: H&E, hematoxylin & eosin; Col2, collagen 2; col1, collagen 10;
SO, Safranin O; Col1, collagen 1; MSC, mesenchymal stem cells. 40X magnifications are
presented.
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Figure 4. Transplanted MSC localize within specific niches of the fracture callus
106 CMVR26-Lac-Z-MSC were transplanted into fractured mice, calluses dissected 7 days
after fracture and X-gal stained. (A): paraffin sections of the β-gal stained calluses were
counter-stained with nuclear Fast Red showing MSC localization into specific areas of the
fracture callus. (B): paraffin sections of β-gal stained calluses were counter-stained with
Safranin O/Fast Green. (C): higher magnification of the open box depicted in B, showed
MSC embedded into the bone matrix as osteoblasts. (D): higher magnification of the close
box depicted in B, showed MSC also integrated into the bone matrix as newly formed
osteocytes. (A, B) scale bar 500 micrometers; (C, D), scale bar 33 micrometers. Sections
were obtained from at least 3 mice. Abbreviations: BM, bone marrow (BM); E, endosteum;
EC, endosteal callus.
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Figure 5. Transplanted MSC express BMP-2 within the fracture and localize at the endosteal site
of the callus
(A): 106 BMP-2-LacZ-MSC were transplanted into fractured mice and 7 days after fracture
the calluses were dissected and X-gal stained. Paraffin sections were counter-stained with
nuclear Fast Red showing that MSC localize and express BMP-2 into the fracture rim and
endosteum. (B): higher magnification of A showing the endosteal localization of MSC
expressing BMP-2. (C): BMP-2-Lac-Z mice were fractured and 7 days post-fracture
calluses were dissected and β-gal stained, paraffin sections were counter-stained with
nuclear Fast Red and showed BMP-2 expression at the fracture ridge. (D): higher
magnification of the fracture rim showing expression of BMP-2. (A, C) scale bar 500
micrometers; (B, D) scale bar 200 micrometers. Sections were obtained from at least 3 mice.
Abbreviations: BMP-2, bone morphogenic protein-2.
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Figure 6. Transplanted MSC have a specific systemic anti-inflammatory effects on the cytokines
released after tibia fracture
Cytokines were measured in sera obtained 1, 3 and 7 days after fracture from mice either
transplanted with MSC or controls (no cells) by LINCOplex immunoassay. Sera were
obtained from at least 4 mice for each group at each corresponding time. #, p<0.05 vs
control at the corresponding time; ##, p<0.01 vs control at the corresponding time by Tukey
post-test. Abbreviations: TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1 β, IL-10,
interleukin 10; IL-13, interleukin 13; IL-6, interleukin 6.; MSC, mesenchymal stem cells.
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Table 1
MSC improve the biomechanical properties of the fracture callus. Fourteen days after tibial fracture, calluses
from mice that were transplanted either with MSC or control (no cells) were dissected and subjected to
distraction-to-failure BMT.
No Cells (n=5) MSC (n=6)
Toughness (N*mm) 0.138 ± 0.044 0.425 ± 0.143b
Ultimate Force (N) 1.803 ± 0.488 2.492 ± 0.829
Stiffness (N/mm) 17.790 ± 8.861 12.000 ± 7.591
Ultimate Displacement (mm) 0.124 ± 0.045 0.308 ± 0.148a
a
p<0.05 versus No cells;
b
p<0.01 versus No cells by Student’s t-test.
Abbreviations: MSC, mesenchymal stem cells; BMT, biomechanical testing; N, Newton.
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